Work

Evaluating LeishPepThera (PepA) as an immuno-therapeutic for Leishmania major infection

Year: 2025

Type: article

Abstract: ) infection model. Among these, Peptide A (PepA) exhibited potent SHP-1 inhibition, enhanced nuclear factor of activated T cells 5 (NFAT5) translocation, and increased nitric oxide (NO) production through inducible nitric oxide synthase (iNOS/Nos2) upregulation. PepA also induced M1 (classically activated) macrophages, restored IL-12, suppressed IL-10 expression, and significantly reduced parasite load. These findings identify PepA ("LeishPepThera") as a promising immunotherapeutic candidate that rebalances host immune signaling to promote parasite clearance in CL.

Source: iScience

DOI: 10.1016/j.isci.2025.114064

Authors: Shweta Khandibharad, Shailza Singh

Institutions: National Centre for Cell Science, Regional Centre for Biotechnology

Language: English

Topic: Research on Leishmaniasis Studies

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,240